Heterocyclic Compounds: Ring compounds having atoms other than carbon in their nuclei. (Grant & Hackh's Chemical Dictionary, 5th ed)Heterocyclic Compounds, Bridged-Ring: A class of organic compounds which contain two rings that share a pair of bridgehead carbon atoms.Nitrogen Compounds: Inorganic compounds that contain nitrogen as an integral part of the molecule.Cyclization: Changing an open-chain hydrocarbon to a closed ring. (McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed)Heterocyclic Compounds, 2-Ring: A class of organic compounds containing two ring structures, one of which is made up of more than one kind of atom, usually carbon plus another atom. The heterocycle may be either aromatic or nonaromatic.Palladium: A chemical element having an atomic weight of 106.4, atomic number of 46, and the symbol Pd. It is a white, ductile metal resembling platinum, and following it in abundance and importance of applications. It is used in dentistry in the form of gold, silver, and copper alloys.Heterocyclic Compounds with 4 or More Rings: A class of organic compounds containing four or more ring structures, one of which is made up of more than one kind of atom, usually carbon plus another atom. The heterocycle may be either aromatic or nonaromatic.Heterocyclic Compounds, 3-Ring: A class of organic compounds containing three ring structures, one of which is made up of more than one kind of atom, usually carbon plus another atom. The heterocycle may be either aromatic or nonaromaticMolecular Structure: The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds.Heterocyclic Compounds, 1-Ring: A class of organic compounds containing a ring structure made up of more than one kind of atom, usually carbon plus another atom. The ring structure can be aromatic or nonaromatic.Magnetic Resonance Spectroscopy: Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING).

*  Dichlorinated heterocyclic compounds and methods of synthesis - Patent # 7045627 - PatentGenius

... compounds, including dichloroflosequinan. The methods of the present invention also comprise the synthesis of ... Compositions of the present invention comprise dichlorinated heterocyclic ... As used herein, a "heterocyclic" compound refers to a compound comprising a ring composed of atoms of more than one kind.. As ... A variety of heterocyclic compounds have been described as having various pharmaceutical applications. However, the synthesis ...
patentgenius.com/patent/7045627.html

*  Heterocyclic Compounds

SYNTHESIS OF ACRIDINIUM COMPOUNDS BY N-ALKYLATION OF ACRIDANS. A method is provided for N-alkylation of acridine compounds by ... SYNTHESIS OF ACRIDINIUM COMPOUNDS BY N-ALKYLATION OF ACRIDANS. A method is provided for N-alkylation of acridine compounds by ... COMPOUND WITH ACRIDAN RING STRUCTURE, AND ORGANIC ELECTROLUMINESCENT ELEMENT. [Problem] To provide an organic compound, as a ... PHENANTHRENE COMPOUNDS FOR ORGANIC ELECTRONIC DEVICES. The invention relates to specific phenanthrenes, the use of the compound ...
sumobrain.com/ICL-C07D219-p2.html

*  UnbeatableSale | Rakuten: The Chemistry of Heterocyclic Compounds, Special Topics in Heterocyclic Chemistry

Special Topics in Heterocyclic Chemistry: UBM9780471672531 from UnbeatableSale , Rakuten.com - United States ...
https://rakuten.com/shop/unbeatablesale/product/UBM9780471672531/

*  Application # 2016/0229812. SALT OF NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR CRYSTAL THEREOF, PHARMACEUTICAL...

An object of the present invention is to provide a compound and pharmaceutical composition showing superior stability and/or ... 0242] The compound A was chosen as a comparative compound. [0243] The test compounds and the comparative compound were each ... 0108] The compound of the formula [7] can be prepared by reacting a compound of the general formula [5] with the compound of ... 0123] The compounds of the general formula [10] can be prepared by reacting the compound of the formula [9] with a compound of ...
patents.com/us-20160229812.html

*  Category:Heterocyclic compounds | Psychology Wiki | FANDOM powered by Wikia

Pages in category "Heterocyclic compounds". The following 2 pages are in this category, out of 2 total. ... Media in category "Heterocyclic compounds". The following 2 files are in this category, out of 2 total. ...
psychology.wikia.com/wiki/Category:Heterocyclic_compounds

*  THE LOCAL ANAESTHETIC PROPERTIES OF CERTAIN HETEROCYCLIC COMPOUNDS | Journal of Pharmacology and Experimental Therapeutics

THE LOCAL ANAESTHETIC PROPERTIES OF CERTAIN HETEROCYCLIC COMPOUNDS Message Subject (Your Name) has forwarded a page to you from ... THE LOCAL ANAESTHETIC PROPERTIES OF CERTAIN HETEROCYCLIC COMPOUNDS. G. A. LEVVY and H. B. NISBET ... THE LOCAL ANAESTHETIC PROPERTIES OF CERTAIN HETEROCYCLIC COMPOUNDS. G. A. LEVVY and H. B. NISBET ... THE LOCAL ANAESTHETIC PROPERTIES OF CERTAIN HETEROCYCLIC COMPOUNDS. G. A. LEVVY and H. B. NISBET ...
jpet.aspetjournals.org/content/65/2/129

*  Synthesis of heterocyclic compounds of biological effect for Mohamed Rania Badawy Bakr

Synthesis of heterocyclic compounds of biological effect for Mohamed Rania Badawy Bakr ... Synthesis of heterocyclic compounds of biological effect for Mohamed Rania Badawy Bakr Author(S). Mohamed Rania Badawy Bakr ... Synthesis of heterocyclic compounds of biological effect for Mohamed Rania Badawy Bakr * ... Synthesis of heterocyclic compounds of biological effect for Mohamed Rania Badawy Bakr ...
philadelphia.edu.jo/newlibrary/eng/english-books/671-english-books/90942-engb-90942

*  A Study of N Heterocyclic Compound as a Potential Lubricating Oil Additive

P. Ouyang and X. M. Zhang, "A Study of N Heterocyclic Compound as a Potential Lubricating Oil Additive", Advanced Materials ... A Study of N Heterocyclic Compound as a Potential Lubricating Oil Additive p.2698 ... A Study of N Heterocyclic Compound as a Potential Lubricating Oil Additive. ... Abstract: A heterocyclic derivative of 3-(N-di-n-butylaminomethyl) quinazolin-4-ones was synthesized and its tribological ...
https://scientific.net/AMR.239-242.2698

*  NOPR: Synthesis, characterization and biological evaluation of some heterocyclic compounds containing ethoxyphthalimide moiety ...

Compound 2 acts as key intermediate for both the series of final compounds. In one pathway, 2 is converted to corresponding ... Synthesis, characterization and biological evaluation of some heterocyclic compounds containing ethoxyphthalimide moiety via ... Structure elucidation is accomplished by elemental analysis and spectral data of the synthesized compounds. Final compounds 5a- ...
nopr.niscair.res.in/handle/123456789/9715

*  CONDENSED HETEROCYCLIC COMPOUND AND COMPOSITION - Patent application

0024] 1) Condensed Heterocyclic Compounds [0025] A first aspect of the present invention is a condensed heterocyclic compound ... condensed heterocyclic compounds and 2) compositions which contain organic materials and the condensed heterocyclic compounds. ... there are provided condensed heterocyclic compounds of the following (1) to (5). [0011] (1) The condensed heterocyclic compound ... 0051] (Method of Production of Condensed Heterocyclic Compound Expressed by Formula (I)) [0052] Among the compounds which are ...
patentsencyclopedia.com/app/20120302675

*  Shodhganga@INFLIBNET: Synthesis of nitrogen, oxygen and sulphur heterocyclic compounds in flavanoids

The Shodhganga@INFLIBNET Centre provides a platform for research students to deposit their Ph.D. theses and make it available to the entire scholarly community in open access ...
shodhganga.inflibnet.ac.in:8080/jspui/handle/10603/73493

*  Sources Sought Notice - CHEMISTRY & TOXICITY OF HETEROCYCLIC COMPOUNDS IN PETROLEUM LABORATORY ANALYTICAL SERVICES - Oil & Gas...

TOXICITY OF HETEROCYCLIC COMPOUNDS IN PETROLEUM LABORATORY ANALYTICAL SERVICES ... Sources Sought Notice - CHEMISTRY & TOXICITY OF HETEROCYCLIC COMPOUNDS IN PETROLEUM LABORATORY ANALYTICAL SERVICES in Press by- ... project "Chemistry and Toxicity of Heterocyclic Compounds in Petroleum." Beginning in 2015 the principal investigator at ... Subject: CHEMISTRY & TOXICITY OF HETEROCYCLIC COMPOUNDS IN PETROLEUM LABORATORY ANALYTICAL SERVICES. Classification Code: 68 - ...
https://oilandgas360.com/sources-sought-notice-chemistry-toxicity-of-heterocyclic-compounds-in-petroleum-laboratory-analytical-services/

*  Structural differences in eight- and ten-membered heterocyclic tin compounds displaying transannular interactions OSn. An...

Two series of heterocyclic tin compounds of general formula [(S{C6H3(CH2)nS}2O)SnR1R2] with different central ring sizes were ... Structural differences in eight- and ten-membered heterocyclic tin compounds displaying transannular interactions OSn. An ... Structural differences in eight- and ten-membered heterocyclic tin compounds displaying transannular interactions OSn. An ... The compounds 5, 7, 8, 10, and 11 were investigated by single-crystal X-ray diffraction. The chloro compounds 7, 8, and 11 ...
https://uaeh.edu.mx/investigacion/productos/4736/

*  Designated organic active ingredient containing (doai) > Heterocyclic carbon compounds containing a hetero ring having...

Compounds, compositions and methods of use. Jul. 26, 1977. 4027027. Pyridyloxyalkyleneamino-phenoxy-propanol-2-compounds. May. ... Heterocyclic carbon compounds containing a hetero ring having chalcogen (i.e., o,s,se or te) or nitrogen as the only ring ... Alkoxy pyridine compounds. Jul. 29, 1980. 4205073. Anti-diarrheal anilino nicotinic acids and method of using same. May. 27, ... Antihypertensive pyridylguanidine compounds. Nov. 8, 1977. 4046896. 1-Methyl-2-(pyridyl-oxymethyl)-5-nitro-imidazoles. Sep. 6, ...
patentgenius.com/class/514/349/7.html

*  Designated organic active ingredient containing (doai) > Heterocyclic carbon compounds containing a hetero ring having...

3-Pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission. Oct. 3, 2000. ... Heterocyclic carbon compounds containing a hetero ring having chalcogen (i.e., o,s,se or te) or nitrogen as the only ring ... Cyclic ether compounds as sodium channel modulators. Jan. 9, 2001. 6166032. Method for controlling tobacco use and alleviating ... Compounds which are specific antagonists of the human NK3 receptor and their use as medicinal products and diagnostic tools. ...
patentgenius.com/class/514/318/15.html

*  Designated organic active ingredient containing (doai) > Heterocyclic carbon compounds containing a hetero ring having...

Heterocyclic carbon compounds containing a hetero ring having chalcogen (i.e., o,s,se or te) or nitrogen as the only ring ... Substituted arylamine compounds and methods of treatment. Dec. 10, 2013. 8598217. Imidazole derivatives and their use as ... Carbinol derivatives having heterocyclic linker. Oct. 8, 2013. 8551982. Benzodioxane inhibitors of leukotriene production. Oct ... Azaazulene compounds. Jul. 23, 2013. 8492373. Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as Axl ...
patentgenius.com/class/514/218.html

*  Designated organic active ingredient containing (doai) > Heterocyclic carbon compounds containing a hetero ring having...

Compounds useful as protein kinase inhibitors. Mar. 19, 2013. 8372832. 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl compounds and ... Heterocyclic carbon compounds containing a hetero ring having chalcogen (i.e., o,s,se or te) or nitrogen as the only ring ... Benzodiazepinone compounds and methods of treatment using same. Mar. 18, 2014. 8673898. Aminodiazepines as toll-like receptor ... Benzodiazepine compound and pharmaceutical composition. Mar. 4, 2014. 8637502. 2,3,4,5-tetrahydro-benzo{B}{1,4}diazepine- ...
patentgenius.com/class/514/221.html

*  Structural differences in eight- and ten-membered heterocyclic tin compounds displaying transannular interactions O---Sn. An...

Two series of heterocyclic tin compounds of general formula [(S{C6H3(CH2)nS}2O)SnR1R2] with different central ring sizes were ... Structural differences in eight- and ten-membered heterocyclic tin compounds displaying transannular interactions O---Sn. An ... Structural differences in eight- and ten-membered heterocyclic tin compounds displaying transannular interactions O???Sn. An ... Structural differences in eight- and ten-membered heterocyclic tin compounds displaying transannular... ...
https://uaeh.edu.mx/investigacion/productos/5282/

*  Addition-Reactions of Heterocyclic-Compounds .74. Products from Dimethyl Acetylenedicarboxylate with Thiourea, Thioamide, and...

Addition-Reactions of Heterocyclic-Compounds .74. Products from Dimethyl Acetylenedicarboxylate with Thiourea, Thioamide, and ... Addition-Reactions of Heterocyclic-Compounds .74. Products from Dimethyl Acetylenedicarboxylate with Thiourea, Thioamide, and ...
irep.ntu.ac.uk/id/eprint/4644/

*  METHOD OF MAKING UP USING AN ADDRESSABLE MATRIX LIGHT SOURCE - Patent application

0395] Said compounds may be in solution or particulate. [0396] The fluorescent compound may be a diketopyrrolopyrrole with ... aromatic or non-aromatic C6-C30 or heterocyclic cycle comprising a total of 5 to 30 links and 1 to 5 heteroatoms; said cycles ... 0583] As an example, a compound A such as an alginate derivative and a compound B such as a calcium salt may be mixed. By way ... The result is an increase in the cohesion of the material including said compound. [0492] The compound may be a simple molecule ...
patentsencyclopedia.com/app/20120017929

*  BOCILLIN FL | CTD

Chemicals ← Heterocyclic CompoundsHeterocyclic Compounds, 2-Ring ← Bicyclo Compounds, Heterocyclic ← Penicillins ← BOCILLIN ... Chemicals ← Heterocyclic CompoundsHeterocyclic Compounds, Bridged-Ring ← Bicyclo Compounds, Heterocyclic ← Penicillins ← ... Bridged Compounds ← Bicyclo Compounds ← Bicyclo Compounds, Heterocyclic ← Azabicyclo Compounds ← beta-Lactams ← Penicillins ← ... Sulfur Compounds ← beta-Lactams ← Penicillins ← BOCILLIN FL 5.. ...
ctdbase.org/detail.go?type=chem&acc=C118961

*  IRF8 Mouse anti-Human, Mouse, PerCP-eFluor 710, Clone: V3GYWCH, eBioscience™ 100μg; PerCP-eFluor 710 IRF8 Mouse anti-Human,...

Heterocyclic Building Blocks * Organic Building Blocks * Organometallic Compounds * Salts and Inorganics * Solvents ...
https://fishersci.co.uk/shop/products/irf8-mouse-anti-human-mouse-percp-efluor-710-clone-v3gywch-ebioscience-1/15599436

*  Dimethyl Sulfoxide, HPLC Grade, 99.9%, Alfa Aesar 4 x 1L Dimethyl Sulfoxide, HPLC Grade, 99.9%, Alfa Aesar

Heterocyclic Building Blocks * Organic Building Blocks * Organometallic Compounds * Salts and Inorganics * Solvents ...
https://fishersci.co.uk/shop/products/dimethyl-sulfoxide-hplc-grade-99-9-alfa-aesar-3/11305607

*  R-9.1 Trivial and semisystematic names retained for naming organic compounds

Heterocyclic substituent groups and cations.. Table 26(a). Hydroxy compounds, ethers, and related substituent groups. Parent ... Heterocyclic parent hydrides.. Table 23(a). Heterocyclic parent hydrides. Priority of precedence.. Table 24. Hydrogenated ... Hydroxy compounds, ethers, and related substituent groups. Substituent groups.. Table 27(a). Carbonyl compounds and derived ... Halogen compounds.. See Also:. R-9.0 Introduction. R-9.2 Bridge Names. R-9.3 "a" Prefixes Used in Replacement Nomenclature. ...
acdlabs.com/iupac/nomenclature/93/r93_671.htm

Heterocyclic amine: Heterocyclic amines, also sometime referred to as HCAs, are chemical compounds containing at least one heterocyclic ring, which by definition has atoms of at least two different elements, as well as at least one amine (nitrogen-containing) group. Typically it is a nitrogen atom of an amine group that also makes the ring heterocyclic (e.Ecuadorian cuisine: Ecuadorian cuisine is diverse, varying with altitude, and associated agricultural conditions. Pork, chicken, beef, and (guinea pig) are popular in the mountainous regions, and are served with a variety of carbohydrate-rich foods, especially rice, corn, and potatoes.Nitrogen trichlorideStilbene photocyclization: Stilbene photocyclization is the coupling of two aromatic carbons in stilbenes upon ultraviolet irradiation. The reaction can be used to form polycyclic aromatic hydrocarbons and heteroaromatics.Basic aromatic ring: Basic aromatic rings are aromatic rings in which the lone pair of electrons of a ring-nitrogen atom is not part of the aromatic system and extends in the plane of the ring. This lone pair is responsible for the basicity of these nitrogenous bases, similar to the nitrogen atom in amines.Palladium(II) chlorideRoquefortine CDolutegravirAffibody molecule: Affibody molecules are small proteins engineered to bind to a large number of target proteins or peptides with high affinity, imitating monoclonal antibodies, and are therefore a member of the family of antibody mimetics. Affibody molecules are used in biochemical research and are being developed as potential new biopharmaceutical drugs.Spin–lattice relaxation in the rotating frame: Spin–lattice relaxation in the rotating frame is the mechanism by which Mxy, the transverse component of the magnetization vector, exponentially decays towards its equilibrium value of zero, under the influence of a radio frequency (RF) field in nuclear magnetic resonance (NMR) and magnetic resonance imaging (MRI). It is characterized by the spin–lattice relaxation time constant in the rotating frame, T1ρ.

(1/1106) Comparison of ultrasmall particles of iron oxide (USPIO)-enhanced T2-weighted, conventional T2-weighted, and gadolinium-enhanced T1-weighted MR images in rats with experimental autoimmune encephalomyelitis.

BACKGROUND AND PURPOSE: Ultrasmall particles of iron oxide (USPIO) constitute a contrast agent that accumulates in cells from the mononuclear phagocytic system. In the CNS they may accumulate in phagocytic cells such as macrophages. The goal of this study was to compare USPIO-enhanced MR images with conventional T2-weighted images and gadolinium-enhanced T1-weighted images in a model of experimental autoimmune encephalomyelitis (EAE). METHODS: Nine rats with EAE and four control rats were imaged at 4.7 T and 1.5 T with conventional T1- and T2-weighted sequences, gadolinium-enhanced T1-weighted sequences, and T2-weighted sequences obtained 24 hours after intravenous injection of a USPIO contrast agent, AMI-227. Histologic examination was performed with hematoxylin-eosin stain, Perls' stain for iron, and ED1 immunohistochemistry for macrophages. RESULTS: USPIO-enhanced images showed a high sensitivity (8/9) for detecting EAE lesions, whereas poor sensitivity was obtained with T2-weighted images (1/9) and gadolinium-enhanced T1-weighted images (0/9). All the MR findings in the control rats were negative. Histologic examination revealed the presence of macrophages at the site where abnormalities were seen on USPIO-enhanced images. CONCLUSION: The high sensitivity of USPIO for macrophage activity relative to other imaging techniques is explained by the histologic findings of numerous perivascular cell infiltrates, including macrophages, in EAE. This work supports the possibility of intracellular USPIO transport to the CNS by monocytes/macrophages, which may have future implications for imaging of human inflammatory diseases.  (+info)

(2/1106) 67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma.

Antilymphoma mouse monoclonal antibody (MoAb) Lym-1, labeled with 67Cu or 131I, has demonstrated promising results in radioimmunotherapy (RIT) for lymphoma. Although 131I has played a central role in RIT thus far, some properties of 67Cu are preferable. A subset of our patients received both 67Cu- and 131I-labeled Lym-1, allowing a comparative evaluation of the two radiopharmaceuticals administered to a matched population of patients. Four patients with B-lymphocytic non-Hodgkin's lymphoma that had progressed despite standard therapy entered trials of 67Cu- and 131I-labeled Lym-1, which were injected 3-26 days apart. Lym-1 was conjugated to 6-[p-(bromoacetamido)benzyl]-1,4,7,11-tetraazacyclotetradecane-N,N ',N",N'"-tetraacetic acid (BAT) via 2-iminothiolane (2IT) and radiolabeled with 67Cu to prepare 67Cu-2IT-BAT-Lym-1; 131I-Lym-1 was preparred by the chloramine-T reaction. Planar imaging was used to quantitate 67Cu-2IT-BAT-Lym-1 or 131I-Lym-1 in organs and tumors daily for 3 days or longer. 67Cu-2IT-BAT-Lym-1 exhibited higher peak concentration in 92% (12 of 13) of tumors and a longer biological half-time in every tumor than 131I-Lym-1. The mean tumor concentration (%ID/g) of 67Cu-2IT-BAT-Lym-1 was 1.7, 2.2, and 2.8 times that of 131I-Lym-1 at 0, 24, and 48 h after injection, respectively. The mean biological half-times of 67Cu-2IT-BAT-Lym-1 and 131I-Lym-1 in tumor were 8.8 and 2.3 days, respectively. Consequently, the mean tumor radiation dose delivered by 67Cu-2IT-BAT-Lym-1 was twice that of 131I-Lym-1, 2.8 (range 0.8-6.7), and 1.4 (range 0.4-35) Gy/GBq, respectively. 67Cu-2IT-BAT-Lym-1 delivered a lower marrow radiation dose than 131I-Lym-1; hence, the tumor:marrow therapeutic indices were 29 and 9.7, respectively. Radiation doses from 67Cu-2IT-BAT-Lym-1 and 131I-Lym-1 to normal tissues were similar except for liver, which received a higher dose from 67Cu-2IT-BAT-Lym-1. Images obtained with 67Cu-2IT-BAT-Lym-1 were superior. Radiation dosimetry data for 67Cu-2IT-BAT-Lym-1 and 131I-Lym-1 agreed with corresponding data from the larger populations of patients from which the matched population for the current study was drawn. In conclusion, 67Cu-2IT-BAT-Lym-1 given to non-Hodgkin's lymphoma patients in close temporal proximity to 131I-Lym-1 exhibited greater uptake and longer retention in tumor, resulting in higher radiation dose and therapeutic index than 131I-Lym-1. These as well as other factors suggest that 67Cu-2IT-BAT-Lym-1 may be superior to 131I-Lym-1 for RIT.  (+info)

(3/1106) Efficacy of RD3-0028 aerosol treatment against respiratory syncytial virus infection in immunosuppressed mice.

RD3-0028, a benzodithiin compound, has antiviral activity against respiratory syncytial virus (RSV) in cell culture. We used a mouse model of RSV infection to determine the in vivo effect of RD3-0028. Cyclophosphamide (CYP)-treated, immunosuppressed mice were inoculated intranasally. The lungs of the mice were removed on day 4. The virus titers of the lungs of RD3-0028-treated mice were compared to the virus titers of the lungs of virus-inoculated, untreated control mice. In an effort to increase the therapeutic effectiveness of this compound, RD3-0028 was administered by aerosol to RSV-infected mice by using a head-exposure system. Aerosols generated from reservoirs containing RD3-0028 (7 mg/ml) administered for 2 h twice daily for 3 days significantly reduced the pulmonary titer of RSV-infected mice. It is clear that the minimal effective dose of RD3-0028 for RSV-infected mice is significantly less than that of ribavirin, the only compound currently available for use against RSV disease. Furthermore, the RD3-0028 aerosol administration appeared to protect the lungs of infected, CYP-treated mice against tissue damage, as evidenced by the preservation of the lung architecture and a reduction in pulmonary inflammatory infiltrates. RD3-0028 aerosol was not toxic for mice at the therapeutic dose. The present study demonstrates the effectiveness of aerosol administration of RD3-0028 for RSV-infected mice.  (+info)

(4/1106) Cancer chemopreventive mechanisms of tea against heterocyclic amine mutagens from cooked meat.

Cooking meat and fish under normal conditions produces heterocyclic amine mutagens, several of which have been shown to induce colon tumors in experimental animals. In our search for natural dietary components that might protect against these mutagens, it was found that green tea and black tea inhibit the formation of heterocyclic amine-induced colonic aberrant crypt foci (ACF) in the rat. Since ACF are considered to be putative preneoplastic lesions, we examined the inhibitory mechanisms of tea against the heterocyclic amines. In the initial studies using the Salmonella mutagenicity assay, green tea and black tea inhibited according to the concentration of tea leaves during brewing and the time of brewing; a 2-3-min brew of 5% green tea (w/v) was sufficient for >90% antimutagenic activity. N-hydroxylated heterocyclic amines, which are direct-acting mutagens in Salmonella, were inhibited by complete tea beverage and by individual components of tea, such as epigallocatechin-3-gallate (EGCG). Inhibition did not involve enhanced mutagen degradation, and EGCG and other catechins complexed only weakly with the mutagens, suggesting electrophile scavenging as an alternative mechanism. Enzymes that contribute to the metabolic activation of heterocyclic amines, namely microsomal NADPH-cytochrome P450 reductase and N, O-acetyltransferase, were inhibited by tea in vitro. Studies in vivo established that tea also induces cytochromes P450 and Phase II enzymes in a manner consistent with the rapid metabolism and excretion of heterocyclic amines. Collectively, the results indicate that tea possesses anticarcinogenic activity in the colon, and this most likely involves multiple inhibitory mechanisms.  (+info)

(5/1106) The Saccharomyces cerevisiae hyperrecombination mutant hpr1Delta is synthetically lethal with two conditional alleles of the acetyl coenzyme A carboxylase gene and causes a defect in nuclear export of polyadenylated RNA.

In a screen for mutants that display synthetic lethal interaction with hpr1Delta, a hyperrecombination mutant of Saccharomyces cerevisiae, we have isolated a novel cold-sensitive allele of the acetyl coenzyme A (CoA) carboxylase gene, acc1(cs), encoding the rate-limiting enzyme of fatty acid synthesis. The synthetic lethal phenotype of the acc1(cs) hpr1Delta double mutant was only partially complemented by exogenous fatty acids. hpr1Delta was also synthetically lethal with a previously isolated, temperature-sensitive allele of ACC1, mtr7 (mRNA transport), indicating that the lethality of the acc1(cs) hpr1Delta double mutant was not allele specific. The basis for the interaction between conditional acc1 alleles and hpr1Delta was investigated in more detail. In the hpr1Delta mutant background, acetyl-CoA carboxylase enzyme activity was reduced about 15-fold and steady-state levels of biotinylated Acc1p and ACC1 mRNA were reduced 2-fold. The reduced Acc1p activity in hpr1Delta cells, however, did not result in an altered lipid or fatty acid composition of the mutant membranes but rendered cells hypersensitive to soraphen A, an inhibitor of Acc1p. Similar to mtr7, hpr1Delta and acc1(cs) mutant cells displayed a defect in nuclear export of polyadenylated RNA. Oversized transcripts were detected in hpr1Delta, and rRNA processing was disturbed, but pre-mRNA splicing appeared wild type. Surprisingly, the transport defect of hpr1Delta and acc1(cs) mutant cells was accompanied by an altered ring-shaped structure of the nucleolus. These observations suggest that the basis for the synthetic lethal interaction between hpr1Delta and acc1 may lie in a functional overlap of the two mutations in nuclear poly(A)+ RNA production and export that results in an altered structure of the nucleolus.  (+info)

(6/1106) Diverse oxygenations catalyzed by carbazole 1,9a-dioxygenase from Pseudomonas sp. Strain CA10.

Carbazole 1,9a-dioxygenase (CARDO) from Pseudomonas sp. strain CA10 is a multicomponent enzyme that catalyzes the angular dioxygenation of carbazole, dibenzofuran, and dibenzo-p-dioxin. It was revealed by gas chromatography-mass spectrometry and 1H and 13C nuclear magnetic resonance analyses that xanthene and phenoxathiin were converted to 2,2',3-trihydroxydiphenylmethane and 2,2',3-trihydroxydiphenyl sulfide, respectively. Thus, for xanthene and phenoxathiin, angular dioxygenation by CARDO occurred at the angular position adjacent to the oxygen atom to yield hetero ring-cleaved compounds. In addition to the angular dioxygenation, CARDO catalyzed the cis dihydroxylation of polycyclic aromatic hydrocarbons and biphenyl. Naphthalene and biphenyl were converted by CARDO to cis-1, 2-dihydroxy-1,2-dihydronaphthalene and cis-2,3-dihydroxy-2, 3-dihydrobiphenyl, respectively. On the other hand, CARDO also catalyzed the monooxygenation of sulfur heteroatoms in dibenzothiophene and of the benzylic methylenic group in fluorene to yield dibenzothiophene-5-oxide and 9-hydroxyfluorene, respectively. These results indicate that CARDO has a broad substrate range and can catalyze diverse oxygenation: angular dioxygenation, cis dihydroxylation, and monooxygenation. The diverse oxygenation catalyzed by CARDO for several aromatic compounds might reflect the differences in the binding of the substrates to the reaction center of CARDO.  (+info)

(7/1106) Pharmacokinetics and pharmacodynamics of Ro 44-3888 after single ascending oral doses of sibrafiban, an oral platelet aggregation inhibitor, in healthy male volunteers.

AIMS: This study constituted the first administration of the oral platelet inhibitor, sibrafiban, to humans. The aim was to investigate the pharmacokinetics and pharmacodynamics of Ro 44-3888, the active principle of sibrafiban, after single ascending oral doses of sibrafiban. Particular emphasis was placed on intersubject variability of the pharmacokinetic and pharmacodynamic parameters of Ro 44-3888. METHODS: The study consisted of three parts. Part I was an open ascending-dose study to determine target effect ranges of sibrafiban. Part II, a double-blind, placebo-controlled, parallel-group study, addressed the intersubject variability of pharmacokinetic and pharmacodynamic parameters of the active principle at a sibrafiban dose achieving an intermediate effect. Part III was a double-blind, placebo-controlled, ascending-dose design covering the complete plasma concentration vs pharmacodynamic response curve of sibrafiban. RESULTS: At sibrafiban doses between 5 mg and 12 mg, the pharmacokinetics of free Ro 44-3888 in plasma were linear whereas those of total Ro 44-3888 were non-linear because of the saturable binding to the glycoprotein IIb-IIIa receptor. Saturation of the GP IIb-IIIa receptor was reached at plasma concentrations of 15.9 ng ml-1. At sibrafiban doses up to 2 mg, ADP-induced platelet aggregation was inhibited by 50%, whereas the inhibition of TRAP-induced platelet aggregation was about 20-30%. At the higher doses, ADP-induced platelet aggregation was almost completely inhibited while a clear dose-response could be observed with TRAP-induced inhibition of platelet aggregation at sibrafiban doses of 5 to 12 mg. Ivy bleeding time increased very steeply with dose with a significant prolongation observed at doses of 5 to 7 mg of sibrafiban (5-7 min, >30 min in one case). At a sibrafiban dose of 12 mg, the stopping criterion for dose escalation (prolongation of the Ivy bleeding time >30 min in three out of four subjects per dose group) was reached. The interindividual coefficients of variation of the integrated pharmacokinetic and pharmacodynamic parameters (AUC and AUE) were below 20%, thus lying well within the pre-set level of acceptance. CONCLUSIONS: With a low intersubject variability of its pharmacokinetic and pharmacodynamic parameters, linear pharmacokinetics and pharmacodynamic effects closely related to its plasma concentrations, Ro 44-3888 has good pharmacological prerequisites for a well controllable therapy of secondary prevention of arterial thrombosis in patients with acute coronary syndrome.  (+info)

(8/1106) Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4.

The emergence of X4 human immunodeficiency virus type 1 (HIV-1) strains in HIV-1-infected individuals has been associated with CD4(+) T-cell depletion, HIV-mediated CD8(+) cell apoptosis, and an impaired humoral response. The bicyclam AMD3100, a selective antagonist of CXCR4, selected for the outgrowth of R5 virus after cultivation of mixtures of the laboratory-adapted R5 (BaL) and X4 (NL4-3) HIV strains in the presence of the compound. The addition of AMD3100 to peripheral blood mononuclear cells infected with X4 or R5X4 clinical HIV isolates displaying the syncytium-inducing phenotype resulted in a complete suppression of X4 variants and a concomitant genotypic change in the V2 and V3 loops of the envelope gp120 glycoprotein. The recovered viruses corresponded genotypically and phenotypically to R5 variants in that they could no longer use CXCR4 as coreceptor or induce syncytium formation in MT-2 cells. Furthermore, the phenotype and genotype of a cloned R5 HIV-1 virus converted to those of the R5X4 virus after prolonged culture in lymphoid cells. However, these changes did not occur when the infected cells were cultured in the presence of AMD3100, despite low levels of virus replication. Our findings indicate that selective blockade of the CXCR4 receptor prevents the switch from the less pathogenic R5 HIV to the more pathogenic X4 HIV strains, a process that heralds the onset of AIDS. In this article, we show that it could be possible to redirect the evolution of HIV so as to impede the emergence of X4 strains or to change the phenotype of already-existing X4 isolates to R5.  (+info)



synthesis


  • The present invention teaches compositions comprising dichloro heterocyclic compounds and the synthesis of the same. (patentgenius.com)
  • However, the synthesis of such compounds, especially on a large scale, is often labor-intensive, expensive and time consuming. (patentgenius.com)
  • What is neededtherefore, is a simplified and economical method for the synthesis and purification of halogenated heterocyclic compounds. (patentgenius.com)

Abstract


  • Abstract: A heterocyclic derivative of 3-(N-di- n -butylaminomethyl) quinazolin-4-ones was synthesized and its tribological behavior as an. (scientific.net)
  • Abstract: A heterocyclic derivative of (n-palmitic acid)-N-quinazolin-4-one methylester was synthesized and its tribological behavior as an ashless. (scientific.net)

organic


  • Problem] To provide an organic compound that, as a material for a high-efficiency, high-durability organic electroluminescent element, has superior hole injection/transport performance, has electron stopping ability, and has the charact. (sumobrain.com)
  • The present invention relates to a novel chemical compound having an acridine structure, and to an organic light-emitting diode using same, and more particularly, to a novel chemical compound having an acridine structure, and to an organ. (sumobrain.com)
  • An organic electroluminescent element including a substrate, a pair of electrodes comprising an anode and a cathode, and organic layers including a light emitting layer, wherein the organic layer contains a compound represented by the fo. (sumobrain.com)
  • A condensed heterocyclic compound which is shown by the following formula (I) and a composition containing an (a) organic material and (b) at least one type of the condensed heterocyclic compound are provided. (patentsencyclopedia.com)
  • The present invention relates to a novel condensed heterocyclic compound which can impart high processing stability and heat resistance, and long life to a polymer or other organic material which is susceptible to oxidation, heat, or light induced breakdown and to a composition which contains an organic material and that condensed heterocyclic compound. (patentsencyclopedia.com)
  • The present invention was made in consideration of the above situation and has as its object the provision of a novel condensed heterocyclic compound which is able to be synthesized easily and has a superior antiaging action on organic materials which are susceptible to oxidation, heat, or light induced breakdown and of a composition which contains an organic material and that condensed heterocyclic compound. (patentsencyclopedia.com)

THEREOF


  • In one embodiment the present invention teaches a dichloro heterocyclic compound corresponding to 3-dichloromethylsulfinyl-7-fluoro-1-methyl-4-quinolone (dichloroflosequinan) and derivative thereof. (patentgenius.com)

Nitrogen


  • A method is provided for N-alkylation of acridine compounds by reduction of acridines to corresponding acridans to improve the reactivity of the acridine nitrogen, and subsequent N-alkylation of the acridans in ionic liquid solvents to p. (sumobrain.com)
  • Subject matter which contains a seven-membered heterocyclic ring consisting of two nitrogen and five carbon atoms. (patentgenius.com)

Chemistry


  • project "Chemistry and Toxicity of Heterocyclic Compounds in Petroleum. (oilandgas360.com)
  • During the continued implementation of this project, additional oil weathering, oil-water-dispersant mixture preparation, fractionation, and analytical chemistry services will be required to improve the understanding of the occurrence and bioavailability of polar compounds in oil-contaminated environmental media, which will guide future studies that test hypotheses relating these compounds to toxicity. (oilandgas360.com)

wherein


  • 11. The condensed heterocyclic compound as set forth in claim 10, wherein in said formula (I), R a and R b respectively independently indicate substitutable linear or branched C 1 to C 2 0 alkyl groups or substitutable phenyl groups. (patentsencyclopedia.com)
  • 12. The condensed heterocyclic compound as set forth in claim 11, wherein in said formula (I), R a and R b respectively independently indicate α-methylbenzyl groups, α,α-dimethylbenzyl groups, t-butyl groups, phenyl groups, or 4-methylphenyl groups. (patentsencyclopedia.com)

Methods


  • The present invention provides for methods for therapeutic use of dimeric compound B3C and related compounds to treat Parkinson's disease (PD) and Parkinsonism. (sumobrain.com)
  • Methods of delivery of those more effective eisp!aiin compounds to the nucleus in cancer ceils is discl. (sumobrain.com)

pharmaceutical


  • A variety of heterocyclic compounds have been described as having various pharmaceutical applications. (patentgenius.com)
  • An object of the present invention is to provide a compound and pharmaceutical composition showing superior stability and/or solubility, etc. and having superior FLT3 inhibitory activity. (patents.com)

present


  • The present invention concerns particular fluorenes, the use of the compound in an electronic device, and an electronic device containing at least one of these compounds. (sumobrain.com)
  • The present invention relates to oncology, in particular to a molecular compound denominated here as "oncoloose", which is capable of selectively destroying solid tumour cells without affecting rapidly replicating healthy cells. (sumobrain.com)
  • Compositions of the present invention comprise dichlorinated heterocyclic compounds, including dichloroflosequinan. (patentgenius.com)
  • The topological analysis indicated that bond critical points are present along the O?Sn direction in the compounds 7, 8, 11, and 12. (edu.mx)

general formula


  • Two series of heterocyclic tin compounds of general formula [(S{C6H3(CH2)nS}2O)SnR1Rwith different central ring sizes were prepared. (edu.mx)

Study


  • Home Advanced Materials Research Advanced Materials, CEAM 2011 A Study of N Heterocyclic Compound as a Potential. (scientific.net)
  • P. Ouyang and X. M. Zhang, "A Study of N Heterocyclic Compound as a Potential Lubricating Oil Additive", Advanced Materials Research, Vols. (scientific.net)

series


  • Compound 2 acts as key intermediate for both the series of final compounds. (niscair.res.in)

least


  • The invention relates to specific phenanthrenes, the use of the compound in an electronic device, and an electronic device containing at least one of said compounds. (sumobrain.com)

STRUCTURE


  • Structure elucidation is accomplished by elemental analysis and spectral data of the synthesized compounds. (niscair.res.in)